Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Emerging therapies for breast cancer.

Hu X, Huang W, Fan M.

J Hematol Oncol. 2017 Apr 28;10(1):98. doi: 10.1186/s13045-017-0466-3. Review.

2.

Phase III Soft Tissue Sarcoma Trials: Success or Failure?

Lee AT, Pollack SM, Huang P, Jones RL.

Curr Treat Options Oncol. 2017 Mar;18(3):19. doi: 10.1007/s11864-017-0457-1. Review.

3.

Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.

Tamura K, Inoue K, Masuda N, Takao S, Kashiwaba M, Tokuda Y, Iwata H, Yamamoto N, Aogi K, Saeki T, Nakayama T, Sato N, Toyama T, Ishida T, Arioka H, Saito M, Ohno S, Yamauchi H, Yamada K, Watanabe J, Ishiguro H, Fujiwara Y.

Cancer Sci. 2017 May;108(5):987-994. doi: 10.1111/cas.13221. Epub 2017 May 5.

4.

Efficacy of eribulin in breast cancer: a short report on the emerging new data.

Eslamian G, Wilson C, Young RJ.

Onco Targets Ther. 2017 Feb 13;10:773-779. doi: 10.2147/OTT.S102638. eCollection 2017. Review.

5.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544. No abstract available.

6.

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.

Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Noda S, Takashima T, Onoda N, Tomita S, Ohsawa M, Hirakawa K, Ohira M.

PLoS One. 2017 Feb 6;12(2):e0170634. doi: 10.1371/journal.pone.0170634. eCollection 2017.

7.
8.

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.

Sampson VB, Vetter NS, Zhang W, Patil PU, Mason RW, George E, Gorlick R, Kolb EA.

Oncotarget. 2016 Dec 27;7(52):86594-86607. doi: 10.18632/oncotarget.13358.

9.

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.

Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC.

ESMO Open. 2016 Jul 4;1(4):e000066. eCollection 2016.

11.

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T.

Onco Targets Ther. 2016 Oct 11;9:6233-6246. eCollection 2016. Review.

12.

Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.

Kitahara H, Hirai M, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S.

Oncol Rep. 2016 Dec;36(6):3139-3144. doi: 10.3892/or.2016.5189. Epub 2016 Oct 21.

13.

Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes.

Giotta F, Acito L, Candeloro G, Del Medico P, Gadaleta-Caldarola G, Giordano G, Gueli R, Lugini A, Magri V, Mandarà M, Masci G, Pisconti S, Pistelli M, Rizzi A, Salesi N, Schirone A, Scognamiglio G, Tedeschi M, Zucchinelli P.

Oncologist. 2016 Oct 14. pii: theoncologist.2016-0022. [Epub ahead of print]

PMID:
27742906
14.

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas.

Noujaim J, Alam S, Thway K, Jones RL.

Indian J Med Paediatr Oncol. 2016 Jul-Sep;37(3):125-30. doi: 10.4103/0971-5851.190359. Review.

15.

Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival.

Thomas C, Movva S.

Onco Targets Ther. 2016 Sep 9;9:5619-27. doi: 10.2147/OTT.S93517. eCollection 2016. Review.

16.

ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.

Oba T, Izumi H, Ito KI.

Oncotarget. 2016 Oct 25;7(43):70011-70027. doi: 10.18632/oncotarget.11727.

17.

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.

Park YH, Kim TY, Im YH, Lee KS, Park IH, Sohn J, Lee SH, Im SA, Kim JH, Kim SH, Lee SJ, Koh SJ, Lee KH, Choi YJ, Cho EK, Lee S, Kang SY, Seo JH, Kim SB, Jung KH.

Cancer Res Treat. 2017 Apr;49(2):423-429. doi: 10.4143/crt.2016.191. Epub 2016 Aug 3.

18.

An update on clinical oncology for the non-oncologist.

Kaliks RA.

Einstein (Sao Paulo). 2016 Apr-Jun;14(2):294-9. doi: 10.1590/S1679-45082016MD3550. Review. English, Portuguese.

19.

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.

Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, Song J, Dutcus CE, Kaufman PA.

Breast Cancer (Auckl). 2016 Jun 28;10:77-84. doi: 10.4137/BCBCR.S39615. eCollection 2016.

20.

"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.

Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder TA, Olivo M, Song J, O'Shaughnessy JA, Jove M, Perez EA.

Breast Cancer Res. 2015 Dec 9;17(1):150. doi: 10.1186/s13058-015-0657-1.

Supplemental Content

Support Center